Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.

Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D.

Ann Surg. 2011 Feb;253(2):328-35. doi: 10.1097/SLA.0b013e3181fd271c.

2.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

3.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

4.

Dose escalation methods in phase I cancer clinical trials.

Le Tourneau C, Lee JJ, Siu LL.

J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. Review.

5.

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.

Maciag PC, Radulovic S, Rothman J.

Vaccine. 2009 Jun 19;27(30):3975-83. doi: 10.1016/j.vaccine.2009.04.041. Epub 2009 May 3.

PMID:
19389451
6.

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E.

Clin Cancer Res. 2008 Mar 1;14(5):1455-63. doi: 10.1158/1078-0432.CCR-07-0371.

7.

Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.

Bahjat KS, Prell RA, Allen HE, Liu W, Lemmens EE, Leong ML, Portnoy DA, Dubensky TW Jr, Brockstedt DG, Giedlin MA.

J Immunol. 2007 Dec 1;179(11):7376-84.

8.

Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells.

Yoshimura K, Laird LS, Chia CY, Meckel KF, Slansky JE, Thompson JM, Jain A, Pardoll DM, Schulick RD.

Cancer Res. 2007 Oct 15;67(20):10058-66.

9.

Mesothelin expression in human lung cancer.

Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I.

Clin Cancer Res. 2007 Mar 1;13(5):1571-5.

10.

Cytosolic entry controls CD8+-T-cell potency during bacterial infection.

Bahjat KS, Liu W, Lemmens EE, Schoenberger SP, Portnoy DA, Dubensky TW Jr, Brockstedt DG.

Infect Immun. 2006 Nov;74(11):6387-97. Epub 2006 Sep 5.

11.

In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.

Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD.

J Immunol Methods. 2006 Mar 20;310(1-2):40-52. Epub 2006 Jan 26.

PMID:
16469329
12.

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.

Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31.

13.

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.

Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D.

Am J Clin Pathol. 2005 Dec;124(6):838-45.

PMID:
16416732
14.

Localization of mesothelin in epithelial ovarian cancer.

Hassan R, Kreitman RJ, Pastan I, Willingham MC.

Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7.

PMID:
16082249
15.

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.

Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Gut. 2005 Nov;54(11):1604-9. Epub 2005 May 29.

16.

Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13.

17.

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM.

J Exp Med. 2004 Aug 2;200(3):297-306.

18.

Mesothelin: a new target for immunotherapy.

Hassan R, Bera T, Pastan I.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. Review.

19.

Application of mesothelin immunostaining in tumor diagnosis.

Ordóñez NG.

Am J Surg Pathol. 2003 Nov;27(11):1418-28.

PMID:
14576474

Supplemental Content

Support Center